MRSN insider transaction filings

Mersana Therapeutics, Inc. — 22 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-01-06. Screen MRSN transaction legs live →

FiledFormInsiderReported transactionsSource
2026-01-064Hack Andrew A. F. — DirectorCode (U): 578 · Code (U): 346,545 · Disposition to issuer (D): 2,460 (derivative) · Disposition to issuer (D): 2,088 (derivative) · Disposition to issuer (D): 400 (derivative) · Disposition to issuer (D): 1,000 (derivative) · +7 moreEDGAR
2026-01-064Diaz Allene M. — DirectorCode (U): 578 · Disposition to issuer (D): 2,460 (derivative) · Disposition to issuer (D): 1,571 (derivative) · Disposition to issuer (D): 416 (derivative) · Disposition to issuer (D): 1,800 (derivative) · Disposition to issuer (D): 734 (derivative) · +1 moreEDGAR
2026-01-064Carvajal Alejandra — SVP, Chief Legal OfficerCode (U): 3,131 · Disposition to issuer (D): 3,047 (derivative) · Disposition to issuer (D): 6,702 (derivative) · Disposition to issuer (D): 4,500 (derivative) · Disposition to issuer (D): 1,800 (derivative) · Disposition to issuer (D): 1,527 (derivative) · +7 moreEDGAR
2026-01-064Bala Mohan — SVP, Chief DevelopmentCode (U): 2,927 · Disposition to issuer (D): 3,515 (derivative) · Disposition to issuer (D): 7,734 (derivative) · Disposition to issuer (D): 1,853 (derivative) · Disposition to issuer (D): 2,646 (derivative) · Disposition to issuer (D): 1,053 (derivative) · +6 moreEDGAR
2026-01-064Alleva Lawrence M — DirectorCode (U): 578 · Code (U): 84 · Disposition to issuer (D): 2,460 (derivative) · Disposition to issuer (D): 800 (derivative) · Disposition to issuer (D): 142 (derivative) · Disposition to issuer (D): 400 (derivative) · +18 moreEDGAR
2026-01-064Huber Martin H. Jr. — President, CEO, DirectorCode (U): 9,573 · Disposition to issuer (D): 5,938 (derivative) · Disposition to issuer (D): 26,713 (derivative) · Disposition to issuer (D): 1,923 (derivative) · Disposition to issuer (D): 99 (derivative) · Disposition to issuer (D): 1,002 (derivative) · +13 moreEDGAR
2026-01-064Mandelia Ashish — VP, Chief Accounting OfficerCode (U): 2,300 · Disposition to issuer (D): 1,687 (derivative) · Disposition to issuer (D): 1,312 (derivative) · Disposition to issuer (D): 2,870 (derivative) · Disposition to issuer (D): 555 (derivative) · Disposition to issuer (D): 44 (derivative) · +12 moreEDGAR
2026-01-064Lowinger Timothy B — SVP, Chief Sci.&Tech. OfficerCode (U): 10,466 · Disposition to issuer (D): 3,047 (derivative) · Disposition to issuer (D): 6,702 (derivative) · Disposition to issuer (D): 696 (derivative) · Disposition to issuer (D): 1,578 (derivative) · Disposition to issuer (D): 713 (derivative) · +16 moreEDGAR
2026-01-064DeSchuytner Brian — SVP, COO & CFOCode (U): 5,015 · Disposition to issuer (D): 3,515 (derivative) · Disposition to issuer (D): 7,734 (derivative) · Disposition to issuer (D): 4,009 (derivative) · Disposition to issuer (D): 5,590 (derivative) · Disposition to issuer (D): 178 (derivative) · +13 moreEDGAR
2026-01-064Protopapas Anna — DirectorCode (U): 6,721 · Code (U): 2,890 · Code (U): 9,609 · Disposition to issuer (D): 2,460 (derivative) · Disposition to issuer (D): 2,500 (derivative) · Disposition to issuer (D): 480 (derivative) · +14 moreEDGAR
2026-01-064Dere Willard H — DirectorCode (U): 1,567 · Disposition to issuer (D): 2,460 (derivative) · Disposition to issuer (D): 800 (derivative) · Disposition to issuer (D): 544 (derivative) · Disposition to issuer (D): 1,000 (derivative) · Disposition to issuer (D): 450 (derivative) · +7 moreEDGAR
2026-01-064Hege Kristen — DirectorCode (U): 578 · Disposition to issuer (D): 2,460 (derivative) · Disposition to issuer (D): 142 (derivative) · Disposition to issuer (D): 400 (derivative) · Disposition to issuer (D): 1,000 (derivative) · Disposition to issuer (D): 450 (derivative) · +12 moreEDGAR
2026-01-064MOTT DAVID M — DirectorCode (U): 23,546 · Code (U): 383 · Disposition to issuer (D): 2,460 (derivative) · Disposition to issuer (D): 264 (derivative) · Disposition to issuer (D): 400 (derivative) · Disposition to issuer (D): 1,011 (derivative) · +9 moreEDGAR
2025-10-284Bala Mohan — SVP, Chief Development OfficerOption exercise (M): 250 @ $0 · Sale (S): 77 @ $9.90 · Option exercise (M): 250 (derivative) @ $0EDGAR
2025-09-154Huber Martin H. Jr. — President, CEO, DirectorOption exercise (M): 6,670 @ $0 · Sale (S): 2,012 @ $7.31 · Option exercise (M): 6,670 (derivative) @ $0EDGAR
2025-06-134Alleva Lawrence M — DirectorGrant/award (A): 61,500 (derivative) @ $0EDGAR
2025-06-134Diaz Allene M. — DirectorGrant/award (A): 61,500 (derivative) @ $0EDGAR
2025-06-134Hack Andrew A. F. — DirectorGrant/award (A): 61,500 (derivative) @ $0EDGAR
2025-06-134Protopapas Anna — DirectorGrant/award (A): 61,500 (derivative) @ $0EDGAR
2025-06-134Dere Willard H — DirectorGrant/award (A): 61,500 (derivative) @ $0EDGAR
2025-06-134Hege Kristen — DirectorGrant/award (A): 61,500 (derivative) @ $0EDGAR
2025-06-134MOTT DAVID M — DirectorGrant/award (A): 61,500 (derivative) @ $0EDGAR

Recent 8-K events — Mersana Therapeutics, Inc.

FiledFormItems reportedSource
2026-01-068-K1.02 — Termination of a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2025-11-148-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2025-11-138-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-09-058-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2025-08-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2025-07-248-K3.03 — Material Modification to Rights of Security Holders
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2025-07-038-K1.02 — Termination of a Material Definitive AgreementEDGAR
2025-06-138-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2025-06-028-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-05-158-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=MRSN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →